DXCM - DexCom Inc Stock Price, Fair Value and News

136.49USD+1.92 (+1.43%)Market Closed

Market Summary

USD136.49+1.92

Market Closed

1.43%

DXCM Alerts

7 major insider sales recently.

DXCM Stock Price

View Fullscreen

DXCM RSI Chart

DXCM Valuation

Market Cap

51.9B

Price/Earnings (Trailing)

95.81

Price/Sales (Trailing)

14.32

EV/EBITDA

56.46

Price/Free Cashflow

101.35

DXCM Price/Sales (Trailing)

DXCM Profitability

Operating Margin

94.62%

EBT Margin

19.61%

Return on Equity

26.18%

Return on Assets

8.64%

Free Cashflow Yield

0.99%

DXCM Fundamentals

DXCM Revenue

Revenue (TTM)

3.6B

Rev. Growth (Yr)

26.9%

Rev. Growth (Qtr)

6.1%

DXCM Earnings

Earnings (TTM)

541.5M

Earnings Growth (Yr)

179.19%

Earnings Growth (Qtr)

112.34%

Breaking Down DXCM Revenue

52 Week Range

80.80139.55

(Low)(High)

Last 7 days

-3.8%

Last 30 days

3.2%

Last 90 days

8.1%

Trailing 12 Months

16.3%

How does DXCM drawdown profile look like?

DXCM Financial Health

Current Ratio

2.84

DXCM Investor Care

Buy Backs (1Y)

0.23%

Diluted EPS (TTM)

1.3

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	3.0B	3.2B	3.4B	3.6B
2022	2.6B	2.7B	2.8B	2.9B
2021	2.0B	2.2B	2.3B	2.4B
2020	1.6B	1.7B	1.8B	1.9B
2019	1.1B	1.2B	1.4B	1.5B
2018	760.6M	832.5M	914.6M	1.0B
2017	599.4M	632.7M	668.7M	718.5M
2016	445.4M	489.8M	534.2M	573.3M
2015	285.1M	319.2M	354.4M	402.0M
2014	177.1M	200.1M	226.2M	259.0M
2013	109.5M	121.8M	141.6M	160.0M
2012	82.2M	84.3M	89.1M	100.0M
2011	53.3M	62.9M	69.5M	76.3M
2010	34.4M	39.2M	43.9M	48.6M
2009	0	0	0	29.7M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed S&P 500 Index

Grufity's Fair Value model takes all the S&P 500 stocks and divides them into separate buckets based on their attractiveness. The 'Very Cheap' bucket of S&P 500 has greatly outperformed S&P 500 Index. Conversely, S&P500 stocks considered 'Very Expensive' by the model underperformed the S&P500 index in the past three years. Grufity Fair Value is available for 2300+ stocks, including 90% of S&P 500 stocks. Grufity's Fair Value Model separates high-return stocks from low-return stocks.

Returns of $10,000 invested in:

Very Cheap Stocks: $17,289
S&P 500 Index: $12,922
Very Expensive Stocks: $11,022

Grufity's Fair Value model does a great job in separating High Performing Stocks from Low Performing ones in the S&P 500 list.

S&P 500 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of DexCom Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 08, 2024	sayer kevin r	sold	-6,864,140	138	-49,633	president ceo and chairman
Mar 28, 2024	brown michael jon	sold	-367,472	140	-2,624	evp chief legal officer
Mar 25, 2024	stern sadie	sold	-579,180	140	-4,137	evp chief human resources
Mar 15, 2024	dolan matthew vincent	sold	-547,259	130	-4,203	evp strategy & corp dev
Mar 12, 2024	stern sadie	sold	-2,715,010	133	-20,321	evp chief human resources
Mar 12, 2024	dolan matthew vincent	sold	-901,896	134	-6,710	evp strategy and corporate
Mar 12, 2024	lawver teri l	sold	-640,333	134	-4,764	evp chief commercial officer
Mar 12, 2024	sayer kevin r	sold	-10,802,800	133	-81,007	president ceo and chairman
Mar 12, 2024	brown michael jon	sold	-1,182,680	134	-8,799	evp chief legal officer
Mar 12, 2024	sylvain jereme m	sold	-1,567,360	134	-11,661	evp chief financial officer

Which funds bought or sold DXCM recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 12, 2024	Range Financial Group LLC	new	-	201,115	201,115	0.10%
Apr 12, 2024	BALDWIN BROTHERS LLC/MA	unchanged	-	48,782	463,119	0.04%
Apr 12, 2024	Global Assets Advisory, LLC	new	-	120,000	120,000	-%
Apr 12, 2024	Riverview Trust Co	new	-	32,040	32,040	0.03%
Apr 12, 2024	HARBOR INVESTMENT ADVISORY, LLC	added	13.09	25,032	119,837	0.01%
Apr 12, 2024	CHANNEL WEALTH LLC	sold off	-100	-2,191,800	-	-%
Apr 12, 2024	CENTRAL VALLEY ADVISORS, LLC	new	-	1,207,950	1,207,950	0.62%
Apr 12, 2024	DNB Asset Management AS	reduced	-9.32	184,495	13,792,300	0.07%
Apr 12, 2024	CHICAGO TRUST Co NA	added	2.99	200,858	1,529,860	0.32%
Apr 12, 2024	GATEWAY INVESTMENT ADVISERS LLC	added	845	9,807,410	10,832,900	0.12%

Are Funds Buying or Selling DXCM?

Are funds buying DXCM calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own DXCM

No. of Funds

DXCM Alerts

7 major insider sales recently.

Unveiling DexCom Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	vanguard group inc	11.51%	44,467,151	SC 13G/A
Jan 25, 2024	blackrock inc.	8.5%	32,851,473	SC 13G/A
Feb 10, 2023	blackrock inc.	8.7%	33,535,680	SC 13G/A
Feb 09, 2023	vanguard group inc	11.34%	43,819,836	SC 13G/A
Jan 27, 2023	blackrock inc.	8.7%	33,882,680	SC 13G/A
Jan 25, 2023	blackrock inc.	8.8%	33,882,680	SC 13G/A
Feb 09, 2022	vanguard group inc	10.74%	10,410,319	SC 13G/A
Feb 09, 2022	fmr llc	-	0	SC 13G/A
Feb 08, 2022	blackrock inc.	8.4%	8,128,454	SC 13G/A
Dec 06, 2021	baillie gifford & co	4.85%	4,700,380	SC 13G/A

Recent SEC filings of DexCom Inc

View All Filings

Date Filed	Form Type	Document
Apr 15, 2024	144	Notice of Insider Sale Intent
Apr 10, 2024	4	Insider Trading
Apr 08, 2024	144	Notice of Insider Sale Intent
Apr 01, 2024	144	Notice of Insider Sale Intent
Mar 29, 2024	4	Insider Trading
Mar 28, 2024	144	Notice of Insider Sale Intent
Mar 26, 2024	4	Insider Trading
Mar 25, 2024	144	Notice of Insider Sale Intent
Mar 25, 2024	144	Notice of Insider Sale Intent
Mar 25, 2024	144	Notice of Insider Sale Intent

Peers (Alternatives to DexCom Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	188.9B	40.1B	-5.73%	4.72%	33.01	4.71	-8.12%	-17.45%
BDX	67.8B	19.5B	-0.88%	-8.17%	53.97	3.48	4.02%	-22.04%
ALGN	22.9B	3.9B	-3.10%	-11.00%	51.41	5.92	3.42%	23.09%
BAX	20.3B	14.8B	-3.77%	-6.99%	7.66	1.37	2.12%	209.17%
MID-CAP
ATR	9.1B	3.5B	-1.99%	15.94%	32.07	2.62	4.97%	18.89%
HSIC	9.1B	12.3B	-5.16%	-14.19%	21.85	0.74	-2.44%	-22.68%
BIO	8.8B	2.7B	-9.88%	-37.29%	-13.77	3.29	-4.68%	82.43%
XRAY	6.4B	4.0B	-5.94%	-24.93%	-47.62	1.62	1.10%	85.84%
AXNX	3.4B	366.4M	-0.71%	17.46%	-565.84	9.37	33.86%	89.83%
PDCO	2.3B	6.6B	-6.94%	-4.63%	11.73	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	-3.79%	-17.24%	-1.94	0.41	7.73%	-1066.14%
ANIK	376.4M	166.7M	-0.35%	-8.55%	-4.55	2.26	6.67%	-456.34%
ANGO	253.5M	324.0M	17.88%	-30.36%	-1.32	0.78	-3.19%	-337.41%
APYX	47.8M	52.3M	-22.91%	-54.00%	-2.55	0.91	17.61%	19.28%
AEMD	3.8M	3.7M	-16.18%	262.50%	-0.31	1.01	5.77%	8.23%

DexCom Inc News

Latest updates

DexCom Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Income Statement (Quarterly)																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	6.1%	1,035	975	871	742	815	770	696	629	698	650	595	505	569	501	452	405	463	396	336	281	338
Gross Profit	5.3%	657	623	546	463	541	494	450	398	473	447	417	344	399	340	284	257	309	247	207	169	223
Operating Expenses	5.2%	440	418	418	415	416	347	373	357	472	329	316	298	295	246	216	223	208	191	207	183	387
S&GA Expenses	8.5%	309	285	297	295	305	235	249	219	237	199	187	189	173	159	136	150	129	124	138	124	112
R&D Expenses	3.6%	136	131	119	119	116	110	122	136	150	129	129	109	119	88.00	80.00	73.00	79.00	67.00	69.00	59.00	58.00
EBITDA Margin	-	0.25*	-	0.21*	0.20*	0.19*	0.16*	0.14*	0.15*	0.15*	0.20*	0.20*	0.20*	0.20*	-	-	-	-	-	-	-	-
Interest Expenses	-	-	-	6.00	5.00	-1.70	5.00	5.00	5.00	-2.50	5.00	5.00	5.00	-42.40	24.00	20.00	15.00	15.00	15.00	15.00	15.00	8.00
Income Taxes	-108.4%	-10.10	120	43.00	16.00	41.00	45.00	24.00	-61.20	12.00	25.00	19.00	-15.20	-257	3.00	-0.10	3.00	2.00	-	1.00	0.00	3.00
Earnings Before Taxes	2.4%	246	240	159	65.00	133	146	75.00	36.00	6.00	112	97.00	41.00	154	75.00	46.00	22.00	94.00	46.00	-9.30	-26.60	-176
EBT Margin	11.7%	0.20*	0.18*	0.16*	0.14*	0.13*	0.09*	0.09*	0.10*	0.10*	0.17*	0.17*	0.16*	-	-	-	-	-	-	-	-	-
Net Income	112.3%	256	121	116	49.00	92.00	101	51.00	97.00	-5.30	87.00	78.00	57.00	411	72.00	46.00	20.00	93.00	46.00	-10.50	-26.90	-179
Net Income Margin	34.9%	0.15*	0.11*	0.11*	0.10*	0.12*	0.09*	0.09*	0.10*	0.09*	0.27*	0.28*	0.29*	-	-	-	-	-	-	-	-	-
Free Cashflow	-62.9%	81.00	219	131	81.00	69.00	185	81.00	-30.60	26.00	139	-39.60	-71.90	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-5.0%	6,265	6,596	6,821	5,516	5,392	4,899	5,217	5,057	4,933	4,776	4,504	4,390	4,291	3,833	3,522	2,448	2,395	2,186	2,066	1,974	1,916
Current Assets	-5.8%	4,426	4,698	5,003	3,767	3,669	3,399	3,809	3,747	3,684	3,656	3,474	3,445	3,425	3,237	3,033	1,996	1,969	1,816	1,744	1,691	1,700
Cash Equivalents	-12.0%	566	644	1,195	623	642	698	735	716	1,053	1,444	1,159	734	818	674	530	585	446	396	709	1,285	1,137
Inventory	12.2%	560	499	421	366	307	311	340	342	357	351	319	290	235	201	165	142	120	120	118	101	71.00
Net PPE	-	-	-	-	1,076	1,056	1,003	943	857	802	742	676	590	515	462	384	346	321	301	253	221	183
Goodwill	-0.4%	25.00	25.00	26.00	26.00	26.00	25.00	26.00	27.00	27.00	24.00	19.00	19.00	19.00	19.00	19.00	19.00	19.00	18.00	19.00	19.00	19.00
Liabilities	-3.1%	4,196	4,328	4,720	3,283	3,260	3,075	2,962	2,868	2,891	2,640	2,506	2,487	2,464	2,334	2,168	1,513	1,512	1,421	1,378	1,305	1,253
Current Liabilities	-7.3%	1,556	1,679	2,070	1,865	1,839	901	807	711	721	735	601	604	614	506	400	343	360	322	288	235	222
Shareholder's Equity	-8.8%	2,069	2,268	2,100	2,233	2,132	1,825	2,256	2,189	2,042	1,912	1,755	1,645	1,552	1,499	1,354	935	883	764	688	669	663
Retained Earnings	33.5%	1,021	765	644	529	480	388	287	236	139	-28.00	-98.90	-161	-78.20	-557	-629	-675	-695	-788	-834	-823	-798
Additional Paid-In Capital	-2.9%	3,515	3,618	2,269	2,306	2,258	2,072	2,029	1,997	2,109	2,322	2,194	2,162	1,727	2,154	2,080	1,707	1,676	1,652	1,620	1,591	1,561
Shares Outstanding	-0.3%	385	386	386	388	386	390	393	389	387	387	386	385	-	-	-	-	-	-	-	-	-
Float	-	-	-	49,400	-	-	-	29,100	-	-	-	41,100	-	-	-	38,500	-	-	-	13,557	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-50.4%	133,600	269,200	190,300	155,400	132,500	293,200	172,800	71,000	105,800	247,300	61,600	27,800	172,000	147,600	154,100	1,900	143,700	94,500	64,500	11,800	33,700
Share Based Compensation	-5.4%	36,900	39,000	39,700	35,200	34,000	30,800	32,600	29,100	26,300	27,500	31,600	28,000	34,100	30,700	30,700	23,900	23,600	24,400	29,700	25,000	24,600
Cashflow From Investing	331.1%	414,900	-179,500	-555,900	-186,700	-194,100	229,300	-144,900	-411,800	-496,100	29,000	363,200	-112,200	-24,000	-9,300	-1,115,300	130,600	-94,300	-412,800	-639,400	131,300	30,900
Cashflow From Financing	0.9%	-631,900	-637,400	939,500	11,200	-1,000	-552,500	-4,300	5,300	-800	10,800	-400	800	-4,900	4,500	906,000	6,500	-100	6,000	-100	4,900	701,600
Buy Backs	-	500,000	-	-	-	-	557,700	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

DXCM Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($) shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Income Statement [Abstract]
Revenue	$ 3,622.3	$ 2,909.8	$ 2,448.5
Cost of sales	1,333.4	1,026.7	768.0
Gross profit	2,288.9	1,883.1	1,680.5
Operating expenses:
Research and development	505.8	484.2	517.1
Collaborative research and development fee	0.0	0.0	87.1
Selling, general and administrative	1,185.4	1,007.7	810.5
Total operating expenses	1,691.2	1,491.9	1,414.7
Operating income	597.7	391.2	265.8
Other income (expense), net	112.7	(0.4)	(9.0)
Income before income taxes	710.4	390.8	256.8
Income tax expense	168.9	49.6	39.9
Net income	$ 541.5	$ 341.2	$ 216.9
Basic net income per share (in usd per share)	$ 1.40	$ 0.88	$ 0.56
Shares used to compute basic net income per share (in shares)	386.0	389.4	386.9
Diluted net income per share (in usd per share)	$ 1.30	$ 0.82	$ 0.53
Shares used to compute diluted net income per share (in shares)	425.5	427.5	428.8

DXCM Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Millions	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 566.3	$ 642.3
Short-term marketable securities	2,157.8	1,813.9
Accounts receivable, net	973.9	713.3
Inventory	559.6	306.7
Prepaid and other current assets	168.3	192.6
Total current assets	4,425.9	3,668.8
Property and equipment, net	1,113.1	1,055.6
Operating lease right-of-use assets	71.4	80.0
Goodwill	25.2	25.7
Intangibles, net	134.5	173.3
Deferred tax assets	419.4	341.2
Other assets	75.0	47.1
Total assets	6,264.5	5,391.7
Current liabilities:
Accounts payable and accrued liabilities	1,345.5	901.8
Accrued payroll and related expenses	171.0	134.3
Current portion of long-term senior convertible notes	0.0	772.6
Short-term operating lease liabilities	21.1	20.5
Deferred revenue	18.4	10.1
Total current liabilities	1,556.0	1,839.3
Long-term senior convertible notes	2,434.2	1,197.7
Long-term operating lease liabilities	80.1	94.6
Other long-term liabilities	125.6	128.3
Total liabilities	4,195.9	3,259.9
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.001 par value, 5.0 million shares authorized; no shares issued and outstanding at December 31, 2023 and December 31, 2022	0.0	0.0
Common stock, $0.001 par value, 800.0 million shares authorized; 407.2 million and 385.4 million shares issued and outstanding, respectively, at December 31, 2023; and 393.2 million and 386.3 million shares issued and outstanding, respectively, at December 31, 2022	0.4	0.4
Additional paid-in capital	3,514.6	2,258.1
Accumulated other comprehensive loss	(16.7)	(11.6)
Retained earnings	1,021.4	479.9
Treasury stock, at cost; 21.8 million shares at December 31, 2023 and 6.9 million shares at December 31, 2022	(2,451.1)	(595.0)
Total stockholders’ equity	2,068.6	2,131.8
Total liabilities and stockholders’ equity	$ 6,264.5	$ 5,391.7

About DexCom Inc

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

CEO	Mr. Kevin Ronald Sayer
WEBSITE	dexcom.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	7500

DexCom Inc Frequently Asked Questions

What is the ticker symbol for DexCom Inc? What does DXCM stand for in stocks?

DXCM is the stock ticker symbol of DexCom Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of DexCom Inc (DXCM)?

As of Mon Apr 15 2024, market cap of DexCom Inc is 51.88 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of DXCM stock?

You can check DXCM's fair value in chart for subscribers.

What is the fair value of DXCM stock?

You can check DXCM's fair value in chart for subscribers. The fair value of DexCom Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of DexCom Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for DXCM so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is DexCom Inc a good stock to buy?

The fair value guage provides a quick view whether DXCM is over valued or under valued. Whether DexCom Inc is cheap or expensive depends on the assumptions which impact DexCom Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for DXCM.

What is DexCom Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Apr 15 2024, DXCM's PE ratio (Price to Earnings) is 95.81 and Price to Sales (PS) ratio is 14.32. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. DXCM PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on DexCom Inc's stock?

In the past 10 years, DexCom Inc has provided 0.308 (multiply by 100 for percentage) rate of return.